Lilly agreed to receive $10 million upfront plus milestones and royalties in a licensing and collaboration deal with AlzeCure for gamma-secretase modulator ACD680, bringing Lilly deeper into Alzheimer’s disease drug discovery. Deal value guidance in reporting suggests total development and commercial upside may exceed $1 billion excluding royalties. Separately, Novartis signed a second molecular glue deal with Orionis Biosciences, paying $40 million upfront and up to $1.4 billion across milestones, to work on challenging therapeutic targets across multiple disease areas. Together, the transactions reinforce how big pharma is continuing to scale molecular glue discovery and pairing it with validated pathway assets where target engagement and back-end milestone structures reduce up-front risk.